You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. 2-HOBA for Treatment of Pulmonary Hypertension

    SBC: MTI Biotech Incorporated            Topic: NHLBI

    PROJECT SUMMARY Although the ubiquity of metabolic problems in pulmonary hypertension (PH) has been known for more than a decade, a wealth of new details on the nature of this problem presents the opportunity for intervention. A combination of experimental work in cells and animals and early trials in humans, suggests that these metabolic problems are part of the causation for PH, and that inactiv ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  2. The re-activatable Yb-169 radiation source: a therapeutic medical device to reduce the risk of brachytherapy and increase adoption

    SBC: PXALPHA, L.L.C.            Topic: NCI

    PROJECT SUMMARY/ABSTRACT: There is currently a technological gap in high-dose-rate brachytherapy (HDR-BT) that has stunted the efficacy of single-fraction HDR-BT monotherapy for prostate cancer patients and is preventing a shift away from invasive interstitial brachytherapy to an intracavitary-only approach for cervical cancer patients. The gap is due to the radiation dose conformity limitations o ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  3. Efficacy of an Electrophile Scavenger in the Prevention of Gastrointestinal Inflammatory Carcinogenesis

    SBC: MTI Biotech Incorporated            Topic: 102

    SUMMARY: Many cancers are recognized to have an inflammatory etiology. Gastric cancer, the third leading cause of cancer deaths worldwide, is the prototype- it is caused by infection with the bacterial pathogen Helicobacter pylori in 90% of cases. For colorectal cancer (CRC), the second leading cause of cancer deaths, inflammatory bowel disease (IBD) is a frequent precursor lesion. This STTR Phase ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  4. 2-HOBA for Treatment of Pulmonary Hypertension

    SBC: MTI Biotech Incorporated            Topic: NHLBI

    PROJECT SUMMARY Although the ubiquity of metabolic problems in pulmonary hypertension (PH) has been known for more than a decade, a wealth of new details on the nature of this problem presents the opportunity for intervention. A combination of experimental work in cells and animals and early trials in humans, suggests that these metabolic problems are part of the causation for PH, and that inactiv ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  5. Development of a Digital Cognitive Screening Test to detect Mild Cognitive Impairment and Dementia in Clinical Settings.

    SBC: EchoWear LLC            Topic: NIA

    Project Summary Alzheimer’s disease and related dementias are a growing health problem in our aging population. Assessment of cognitive functioning for early detection is critical to identify individuals who might benefit from treatment with the available symptomatic medications for mild dementia as well as future disease-modifying therapies that are actively under development and being tested i ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  6. Evaluation of In Vivo Efficacy of a Novel Microbial Therapy to Treat Cognitive Deficits in Alzheimers disease

    SBC: PROBIOME THERAPEUTICS, INC.            Topic: NIA

    PROJECT SUMMARY/ABSTRACT Alzheimer’s disease (AD) is a leading cause of dementia, yet no effective therapeutic intervention is available for those in prodromal and early stages of AD. Restoration of functional and cognitive resilience in early disease stages is especially beneficial in many aspects as it could substantially extend the period of quality of life and delay the clinical onset of AD. ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  7. Promoting adult hippocampal neurogenesis in Alzheimer's Disease using an antibody-based therapy

    SBC: BOLDEN THERAPEUTICS, INC.            Topic: R

    PROJECT SUMMARY Alzheimer's disease (AD) is a looming public health crisis that threatens millions of patients' ability to experience healthy aging. In addition to the challenges that AD poses to patients, healthcare providers and caregivers, there is also tremendous economic burden associated with AD and related dementias – estimated to be well over $200B/year in the United States alone. Hundre ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  8. SnapCap: a device to decontaminate central venous catheters (CVC) with 5 snaps

    SBC: Contech Medical, Inc.            Topic: NICHD

    Project Summary/Abstract We propose a new approach to the decontamination of central venous catheters and the prevention of central line-associated bloodstream infections (CLABSI), an important healthcare-associated infection. CLABSIs cost the US healthcare system approximately $2.3 billion annually (Pronovost, NEJM, 2009). Additionally, CLABSIs can be life threatening, especially in the very youn ...

    STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  9. Developing Nanopieces, a Platform RNAi Delivery Technology for Treatment of Multiple Diseases

    SBC: Nanode Therapeutics, Inc.            Topic: NCATS

    STTR_Developing Nanopieces 7. Project Summary/Abstract The bottleneck of developing new RNAi (RNA Interference) drugs is the lack of highly efficient and non-toxic RNA delivery to non-liver tissues in vivo. It is especially challenging to deliver negatively-charged nucleic acid into avascular, dense, and negatively-charged matrix in hard-to-reach tissues including joint cartilage. NanoDe Therapeut ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  10. Multi-fold increase in the production of pharmaceutical insulin with Microbial Stem Cell Technology

    SBC: ASIMICA, INC.            Topic: 300

    PROJECT SUMMARY / ABSTRACT The goal of this project is to demonstrate the feasibility of a novel technology that is expected to boost yields from pharmaceutical industrial insulin production by greater than four-fold over conventional methods. Higher yields will lower production costs, generating savings that will ultimately be passed onto the millions of diabetic patients who require daily insuli ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government